Alpha Cognition (NASDAQ:ACOG) Coverage Initiated by Analysts at Maxim Group

Equities researchers at Maxim Group assumed coverage on shares of Alpha Cognition (NASDAQ:ACOG) in a research note issued to investors on Friday. The firm set a “buy” rating and a $12.00 price target on the stock. Maxim Group’s target price points to a potential upside of 102.02% from the stock’s previous close.

Other research analysts also recently issued reports about the company. Craig Hallum assumed coverage on Alpha Cognition in a research report on Friday, April 17th. They issued a “buy” rating and a $14.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Alpha Cognition in a research report on Friday, May 22nd. Finally, Wall Street Zen cut Alpha Cognition from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $14.67.

Alpha Cognition Stock Performance

Shares of ACOG stock opened at $5.94 on Friday. The stock’s 50 day simple moving average is $6.07 and its 200 day simple moving average is $5.90. Alpha Cognition has a twelve month low of $4.50 and a twelve month high of $11.54. The company has a market capitalization of $129.31 million, a price-to-earnings ratio of -4.40 and a beta of 2.38.

Alpha Cognition (NASDAQ:ACOG) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.04. Alpha Cognition had a negative return on equity of 58.35% and a negative net margin of 232.23%.The business had revenue of $3.53 million for the quarter, compared to the consensus estimate of $3.42 million. On average, analysts forecast that Alpha Cognition will post -1.34 EPS for the current fiscal year.

Institutional Trading of Alpha Cognition

Institutional investors have recently bought and sold shares of the stock. Green Alpha Advisors LLC acquired a new stake in Alpha Cognition in the 4th quarter valued at $72,000. Geode Capital Management LLC acquired a new stake in Alpha Cognition in the 2nd quarter valued at $112,000. Berkshire Asset Management LLC PA boosted its stake in Alpha Cognition by 50.7% in the 3rd quarter. Berkshire Asset Management LLC PA now owns 17,824 shares of the company’s stock valued at $116,000 after buying an additional 6,000 shares in the last quarter. Massar Capital Management LP acquired a new stake in Alpha Cognition in the 2nd quarter valued at $116,000. Finally, Two Sigma Investments LP acquired a new stake in Alpha Cognition in the 3rd quarter valued at $148,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.